CD274 and non-small cell lung carcinoma: This is reminiscent of the updated analysis of a phase II trial that reported intracranial ORR of 27.3% in PD-L1-positive patients with NSCLC and untreated BrMs received pembrolizumab, while no BrM response was observed in PD-L1-negative cohort [10], suggesting the importance of appropriate biomarker selection in treatment decision for this population.